Immutep and Eddingpharm start production of ImmuFact(R) IMP321 at WuXi AppTec in China
WuXi AppTec will manufacture ImmuFact(R) IMP321 to US, European and Chinese GMP standards for Immutep and Eddingpharm
Orsay, France and Shanghai, China, 8 April 2014 – Immutep S.A., the biopharmaceutical company specializing in immuno-oncology, and Eddingpharm have started production of Immutep’s ImmuFact(R) IMP321 (a LAG-3Ig fusion protein) at WuXi AppTec facilities in China. The product is being produced to European, U.S. and Chinese GMP standards.
WuXi AppTec has initiated process development for Immutep’s lead product using Immutep's newly developed proprietary cell line. Immutep is additionally providing full technical support for the development of the production. Immutep and Eddingpharm will develop the product in combination with first-line chemotherapy in metastatic cancer.
Like the checkpoint inhibitors that remove the brake on the CD8 T cells and greatly extend survival in metastatic cancer, antigen presenting cell (APC) activators also increase the T cell response against tumors. ImmuFact(R) IMP321 (a first-in-class APC activator) can be used in combination with first-line chemotherapy or in combination with checkpoint inhibitors.
The mechanism of action of Immutep’s synergistic combination of chemotherapy and active immunotherapy is unique. Chemotherapy provides a burst of tumor cell debris, and the surrounding APCs take up the tumor antigens. ImmuFact(R) IMP321 activates these APC’s, resulting in a long-lasting CD8 T cell response against the tumor.
"We have been very impressed by WuXi's know how and motivation,” said Dr. Frederic Triebel, Scientific and Medical Director of Immutep. “This deal is important for Immutep to continue the development of APC activators in the expanding field of immuno-oncology, in Europe, the USA and Japan. We are in partnering discussions at present.”
“Eddingpharm is excited to be entering the new field of immuno-oncology with Immutep. We believe that immuno-oncology will revolutionize cancer treatment," said Xin Ni, Chairman and CEO of Eddingpharm. "We are working closely with Immutep to develop IMP321.”
“Manufacturing IMP321, a first-in-class biologics in China, showcases WuXi’s solid capability as the gateway for developing novel biologics in China with global standards,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “Once manufacturing is complete, we will achieve the first industry milestone of using the same CMC package, developed at WuXi, for global registration in US, Europe and China.”
人生一定要有的八個朋友: 推手(Builder)、 支柱(Champion)、 同好(Collaborator)、 夥伴(Companion)、 中介(Connector)、 開心果(Energizer)、 開路者(Mind Opener)、 導師(Navigator)。 chutze@bostonorange.com ******************* All rights of articles and photos on this website are reserved.
網頁
- 大波士頓時事新聞
- 波士頓亞美電影節/ Boston International Kids Film Festival
- 波士頓華埠社區中心/華美福利會/華埠社區聯盟/ 華人醫務中心/ 亞美社區發展協會/ 華夏文化協會
- AAC TAP CACAB NAAAP AARW AAWPI ASPIRE AWH WANG YMCA QARI
- 音樂 - 中華表演藝術基金會 4/13 廖國偉
- 波士頓移民進步辦公室通訊/ Office of Women's Advancement/ Community Preservation Act
- 商會 - ACE Nextgen, 128 Cute, OCEAN, TCCNE, TCCYNE,波克萊台商會,波士頓華商會,波士頓亞裔房東會
- 創業 - Startup Boston now available on web
- Plays - Huntington, Boston Lyric, Company One
- 包氏文藝中心通訊 Nov.
- 博物館 - Guggenheim Presents Wu Tsang: Anthem, Opening July 23
- Mass Innovation Nights March 2024 / Innovation Women
- 生物醫藥 - BTBA Mentor/Mentee 招募 開跑
- Mass Life Science Center 10/4
- Greentown Labs newsletter /MIT ClimateTech
- BIOVision/ Boston MedTech / Mass Life Sciences
- Mass BIO / LaunchBIO
- 麻州州長動態 - Nominates Rachel Hershfang as Associate Justice of the Appeals Court and Asha White as Circuit Justice of the District Court
- 波士頓市、昆士市,摩頓市、羅爾市
- Elections
- Boston City Councilor's updates
- BCA - Brooke Stewart Constructs a Love Letter to Boston Artists 4/29
- MIPIM 2021 - International investors return to Cannes for MIPIM September Edition
- 大學沙龍 第204期 王寅麗——阿倫特和波考克關於美國革命的共和論論述
- 朱学渊 - 為中國史學的實證化而努力
訂閱:
發佈留言 (Atom)
沒有留言:
發佈留言